Six-month prospective study of quality of life in Guillain-Barre syndrome.
Guillain-Barre syndrome
Individualized Neuromuscular Quality of Life Questionnaire
disability
prospective study
quality of life
Journal
Acta neurologica Scandinavica
ISSN: 1600-0404
Titre abrégé: Acta Neurol Scand
Pays: Denmark
ID NLM: 0370336
Informations de publication
Date de publication:
Mar 2020
Mar 2020
Historique:
received:
15
08
2019
revised:
01
11
2019
accepted:
06
11
2019
pubmed:
11
11
2019
medline:
23
6
2020
entrez:
10
11
2019
Statut:
ppublish
Résumé
Guillain-Barre syndrome (GBS) is an acute disease of the peripheral nerves and their roots. Quality of life (QoL) in the first year after acute episode of GBS is still underresearched area. The aim of our study was to investigate QoL in GBS patients during a 6-month follow-up period. Multicentric, prospective study included 74 adult patients with GBS (54% males). GBS disability scale (GDS) was used to assess functional disability (severe disability GDS > 2), and Individualized Neuromuscular Quality of Life Questionnaire (INQoL) to asses QoL. Patients were tested on day 14, day 28, month 3, and month 6 from symptom onset. Disability as measured by GDS improved during time (P < .01). INQoL scores also improved during time (P < .01) but were not able to differentiate between day 14 and day 28, and some scores also did not make difference between month 3 and 6 (pain, social relations, emotions and total INQoL score; P > .05). Pooled GDS scores correlated with pooled INQoL scores, especially with independence, activities, and weakness subscores (P < .01). Multiple linear regression analysis showed that GDS at day 14 (β = .52, P < .01) and fatigue score at day 14 (β = .41, P < .01) were independent predictors of the worse GDS at month 6 (adjusted R During a 6-month follow-up period of GBS patients, we observed a gradual recovery of patients' disability and QoL. Our study confirms the importance of patient-reported outcomes and their ability to capture some important issues that are omitted by classic ability measures such as GDS.
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
236-241Informations de copyright
© 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
van den Berg B, Walgaard C, Drenthen J, Fokke C, Jacobs BC, van Doorn PA. Guillain-Barré syndrome: pathogenesis, diagnosis, treatment and prognosis. Nat Rev Neurol. 2014;10:469-482.
Leonhard SE, Mandarakas MR, Gondim FAA, et al. Diagnosis and management of Guillain-Barré syndrome in ten steps. Nat Rev Neurol. 2019;15(11):671-683.
Martic V, Bozovic I, Berisavac I, et al. Three-year follow-up study in patients with Guillain-Barré syndrome. Can J Neurol Sci. 2018;45(3):269-274.
Rekand T, Gramstad A, Vedeler CA. Fatigue, pain and muscle weakness are frequent after Guillain-Barre syndrome and poliomyelitis. J Neurol. 2009;256:349-354.
Farmakidis C, Inan S, Milstein M, Herskovitz S. Headache and pain in Guillain-Barré syndrome. Curr Pain Headache Rep. 2015;19(8):40.
Drory VE, Bronipolsky T, Bluvshtein V, Catz A, Korczyn AD. Occurrence of fatigue over 20 years after recovery from Guillain-Barré syndrome. J Neurol Sci. 2012;316(1-2):72-75.
Bersano A, Carpo M, Allaria S, Franciotta D, Citterio A, Nobile- OE. Long term disability and social status change after Guillain-Barré syndrome. J Neurol. 2006;253(2):214-218.
Jacobs BC, van den Berg B, Verboon C, et al. International Guillain-Barré Syndrome Outcome Study: protocol of a prospective observational cohort study on clinical and biological predictors of disease course and outcome in Guillain-Barré syndrome. J Peripher Nerv Syst. 2017;22(2):68-76.
Bernsen RA, de Jager AE, Kuijer W, van der Meche FG, Suurmeijer TP. Psychosocial dysfunction in the first year after Guillain-Barre syndrome. Muscle Nerve. 2010;41:533-539.
Merkies IS, Schmitz PI, van der Meche FG, Samijn JP, van Doorn PA. Quality of life complements traditional outcome measures in immune-mediated polyneuropathies. Neurology. 2002;59:84-91.
Forsberg A, Press R, Holmqvist LW. Residual disability 10 years after falling ill in Guillain-Barre syndrome: a prospective follow-up study. J Neurol Sci. 2012;317:74-79.
Darweesh SK, Polinder S, Mulder MJ, et al. Health-related quality of life in Guillain-Barré syndrome patients: a systematic review. J Peripher Nerv Syst. 2014;19:24-35.
Vincent KA, Carr AJ, Walburn J, Scott DL, Rose MR. Construction and validation of a quality of life questionnaire for neuromuscular disease (INQoL). Neurology. 2007;68:1051-1057.
Symonds T, Randall JA, Campbell P. Review of patient-reported outcome measures for use in myotonic dystrophy type 1 patients. Muscle Nerve. 2017;56:86-92.
Peric S, Sansone V, Lavrnic D, et al. Serbian validation of the Individualized Neuromuscular Quality of Life Questionnaire (INQoL) in adults with myotonic dystrophy type 1. J Neurol Res. 2011;1:153-160.
Sejvar JJ, Kohl KS, Gidudu J, et al. Guillain-Barre syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine. 2011;29:599-612.
Dimachkie MM, Barohn RJ. Guillain-Barré syndrome and variants. Neurol Clin. 2013;31(2):491-510.
Hughes RA, Newsom-Davis JM, Perkin GD, Pierce JM. Controlled trial prednisolone in acute polyneuropathy. Lancet. 1978;2:750-753.
Forsberg A, Press R, Einarsson U, de Pedro-Cuesta J, Holmqvist LW. Disability and health-related quality of life in Guillain - Barré syndrome during the first two years after onset: a prospective study. Clin Rehabil. 2005;19:900-909.
Hughes RA, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain-Barré syndrome. Cochrane Database Syst Rev. 2012;(7):CD002063.
Walgaard C, Lingsma HF, Ruts L, van Doorn PA, Steyerberg EW, Jacobs BC. Early recognition of poor prognosis in Guillain-Barré syndrome. Neurology. 2011;76(11):968-975.
Peric S, Heatwole C, Durovic E, et al. Prospective measurement of quality of life in myotonic dystrophy type 1. Acta Neurol Scand. 2017;136(6):694-697.
Sansone VA, Ricci C, Montanari M, et al. Measuring quality of life impairment in skeletal muscle channelopathies. Eur J Neurol. 2012;19(11):1470-1476.
Bussmann JB, Garssen MP, van Doorn PA, Stam HJ. Analysing the favourable effects of physical exercise: relationships between physical fitness, fatigue and functioning in Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy. J Rehabil Med. 2007;39(2):121-125.
Demir SO, Köseoğlu F. Factors associated with health-related quality of life in patients with severe Guillain-Barré syndrome. Disabil Rehabil. 2008;30(8):593-599.
Merkies ISJ, Kieseier BC. Fatigue, pain, anxiety and depression in Guillain-Barré syndrome and chronic inflammatory demyelinating polyradiculoneuropathy. Eur Neurol. 2016;75(3-4):199-206.
Roodbol J, de Wit M-CY, Aarsen FK, Catsman-Berrevoets CE, Jacobs BC. Long-term outcome of Guillain-Barré syndrome in children. J Peripher Nerv Syst. 2014;19(2):121-126.
Khan F, Pallant JF, Ng L, Bhasker A. Factors associated with long-term functional outcomes and psychological sequelae in Guillain-Barre syndrome. J Neurol. 2010;257(12):2024-2031.
Koeppen S, Kraywinkel K, Wessendorf TE, et al. Long-term outcome of Guillain-Barré syndrome. Neurocrit Care. 2006;5(3):235-242.
Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome. Lancet. 1997;349(9047):225-230.